Vigeo Therapeutics To Present New Phase 1/2 VT1021 Dose Escalation And Expansion Data At The Society For Immunotherapy Of Cancer's 2020 Annual Meeting

Media coverage

• Title	Vigeo Therapeutics To Present New Phase 1/2 VT1021 Dose Escalation And Expansion Data At The Society For Immunotherapy Of Cancer's 2020 Annual Meeting
  Media name/outlet	TheStreet.com
  Country	United States
  Date	11/9/20
  Persons	Devalingam Mahalingam

• Title	Vigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting; 75% of Patients Who Achieved a Partial Response or Stable Disease Had High Expression of Both CD47 and
  Media name/outlet	PR Newswire
  Country	United States
  Date	11/9/20
  Persons	Devalingam Mahalingam